Investor Relations

Defining a new hundred-billion-level treatment category and market track.

Project Investment Highlights

Track Scarcity

The world's first new paradigm of "Immune Surgery and Universal Treatment for various solid tumors", leading a forward-looking blank track with an ocean market worth hundreds of billions.

Clinical Advantage

80,000+ patients treated over 26 years across 10+ countries. A 92.65% disease benefit rate (CR+PR+SD) in a published 2,836-patient cohort. Extremely low severe adverse reaction rate of only 0.19%.

Efficient Filing Path

IOS-1 granted orphan drug designation by FDA and eligible for Moonshot / 21st Century Cures Act support. FDA 505(b)(2) pathway allows use of existing studies — faster and less costly than a ground-up NDA.

Huge Growth Potential

A single indication (like pancreatic cancer) can support a market space of billions. Expanding to 19 other rare tumors and high-incidence solid tumors.

Mark Harris Testimonial

Clinical Validation: A Patient's Journey

Real-world evidence of our platform's life-saving potential.

"I was diagnosed with Stage 4 Prostate Cancer in June 2016... After 4 treatments of SONATA cancer therapy... my UCLA Health System Oncologist advised that all cancerous lesions that had been in my bones had disappeared."

- Mark E. Harris (US Patient)

The Power of Trust & Efficacy
  • 2016 - Defying the Odds: Top US medical systems offered little hope for his Stage 4 Prostate Cancer with systemic bone metastasis. Our Immune Slow Release Therapy eliminated the bone metastases within months.
  • 2023 - Returning for Hope: When his wife was diagnosed with lung cancer and conventional chemotherapy failed, Mark did not hesitate to cross the ocean again to seek Dr. Yu's treatment.
  • Investment Implication: Deep patient trust built on undeniable clinical outcomes, demonstrating significant advantages over traditional therapies in late-stage, complex oncology cases.
Business Model

"1+1+1" Three-Track Revenue Model

A value upgrade from "treatment plan" to "treatment platform" with diversified and highly resilient revenue structure.

1
Track 1: Direct Sales (To H/B)

Sales of core products (IOS-1) and specialized devices to large and medium-sized hospitals globally.

2
Track 2: Platform Empowerment (To B)

Solution licensing and technical services for a wide medical network (SaaS + consumables model).

3
Track 3: Ecosystem Co-construction

A global partnership program for national/regional markets forming joint ventures.

FDA 505(b)(2) approval pathway and Moonshot eligibility

A Faster Regulatory Path

Eligible under the Moonshot / 21st Century Cures Act with FDA's Oncology Center of Excellence.

  • Up to $12M in annual grant funding
  • Assigned FDA human resources
  • Orphan drug & fast-track status
  • 7-year US market exclusivity
  • US patent restoration eligibility

The FDA 505(b)(2) approval pathway allows approval inputs from existing studies — including those not completed by IOS — significantly reducing cost and timeline versus a traditional NDA.

Proven Global Reach

80,000+ patients treated over the last 26 years, including 255 patients from more than 10 countries — among them the United States.

Patients have traveled from the US, Japan, and elsewhere for treatment, and our platform has already been validated across a broad range of solid tumors and disease stages, providing a deep real-world evidence base ahead of formal FDA registration trials.

80,000 patients treated over 26 years across 10+ countries International patients treated

Financing & IPO Roadmap

Series A Funding Requirement: $50 Million

To systematically advance the core pipeline IOS-1 new drug from pharmaceutical development to listing applications in China and the United States (IND approval to NDA/BLA submission).

Targeting NASDAQ Capital Market

Projecting IPO between 2028 and 2029 to build international credibility and realize liquidity premium.